Antiviral Therapy 14:
|
|
- Erik Terry
- 5 years ago
- Views:
Transcription
1 Antiviral Therapy 14: Short communication A Phase I study to explore the activity and safety of SCH53276, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients Sarah L Pett 1,2 *, Michael C McCarthy 3, David A Cooper 1,2, Karen MacRae 1, Amol Tendolkar 3, Richard Norris 1, Julie M Strizki 3, Kenneth M Williams 4,5 and Sean Emery 2 1 HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia 2 National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Darlinghurst, Sydney, Australia 3 Schering Plough Research Institute, Kenilworth, NJ, USA 4 Clinical Trials Centre, St Vincent s Hospital, Sydney, Australia 5 Clinical Pharmacology Department, St Vincent s Hospital and University of New South Wales, Darlinghurst, Sydney, Australia *Corresponding author: spett@nchecr.unsw.edu.au Background: SCH53276 is a novel small molecule chemokine receptor-5 (CCR5) antagonist with high in vitro potency (mean 9% inhibitory concentration [IC 9 ] nm) against diverse HIV type-1 (HIV-1) isolates. Methods: A single arm study was undertaken to examine the safety, antiviral activity and pharmacokinetics (PK) of 1 days of SCH53276 coadministered with ritonavir (RTV). The trial enrolled formerly treated (off therapy >3 months) or untreated HIV-1-infected patients. Results: The study enrolled males with CD4 + T-cell count >1 cells/µl. Median (range) CD4 + T-cell count was 327 cells/µl (117 1,8), HIV-1 RNA was 4.6 log 1 copies/ml ( ) and patients had phenotypically confirmed R5-tropic HIV-1 only. Mean (95% confidence interval) changes from baseline plasma HIV-1 RNA at days 1 and 15 (4 days off SCH53276) were log 1 copies/ ml ( ) and log 1 copies/ml ( ), respectively. Day 1 median (range) time to maximum plasma concentration, mean (±sd) effective half-life and mean (±sd) trough concentration were 1.4 h (1. 4.), 39.4 h (±14.5) and 178 ng/ml (±34), respectively. All virus isolates remained R5-tropic pre-study, on study and at study end. There were no laboratory or QTc interval changes reportable as adverse events. In total, 11 patients reported 1 treatment emergent adverse event, most commonly gastrointestinal upset. One serious adverse event, pericarditis (grade 2), occurred 13 days after drug administration. It was considered to be possibly related to study drug. Conclusions: Overall, SCH53276 with RTV was safe, generally well tolerated and active against HIV-1 over 1 days of dosing. In this setting, SCH53276 trough concentrations exceed the mean in vitro IC 9 (1.1 ng/ml) by >3-fold (after correction for 8% plasma protein binding) and provide a PK rationale for the observed efficacy. Introduction Chemokine receptor-5 (CCR5) and CXCR4 are key coreceptors for HIV type-1 (HIV-1) entry [1]. Clinical studies have confirmed the antiviral activity of the CCR5 antagonists maraviroc [2,3] and vicriviroc [4,5]; the former has gained approval for use in patients with multidrug-resistant R5-tropic HIV-1. Vicriviroc is in Phase III clinical development. SCH53276 is a new small molecule CCR5 antagonist with high potency and bioavailability. In vitro data show that SCH53276 inhibits the replication of 3 different HIV-1 isolates, with a mean 9% inhibitory concentration (IC 9 ) value of 1.1 ng/ml; resistance to SCH53276 is still currently under investigation. A rising single-dose study of SCH53276 (5 2, mg) in healthy volunteers found that the drug was rapidly absorbed with a time to maximum plasma concentration (T max ) of 1 2 h and a halflife (t ½ ) of 8 11 h (unpublished data). A rising multidose (RMD) study in healthy volunteers randomized to 5 days of SCH53276 (1, 15, 6 or 15 mg twice daily) found all doses were well tolerated. Maximum plasma drug concentration (C max ) and area under the plasma concentration time curve (AUC) increased in a greater-than-dose proportional manner on days 1 and 5. In vitro and animal studies indicate that SCH International Medical Press
2 SL Pett et al. elimination is via hepatic oxidative metabolism by the cytochrome P45 enzyme CYP3A4 followed by conjugation (chiefly glucuronidation; unpublished data). In vitro inhibition of UGT1A1 by SCH53276 has not been assessed. Therefore, the potential for an interaction of raltegravir, a UGT1A1 substrate, is unknown. These data suggest that ritonavir (RTV) would augment the pharmacokinetic (PK) profile of SCH53276 via CYP3A4 inhibition [6]. This was confirmed in those RMD volunteers on the 6 mg twice daily arm who received a further 1 days of SCH53276 with RTV (1 mg once daily). Mean SCH53276 C max increased sixfold ( ng/ml), AUC increased 11-fold (252 2,88 ng/h/ml), minimum plasma concentration (C min ) increased 18-fold (1.3 1,89 ng/ml) and t ½ had a twofold increase ( 26 h; unpublished data). The Phase I study described here enrolled HIV-1- infected individuals who were about to start or resume combination antiretroviral therapy. It was designed to further examine the safety, antiviral activity and PK of SCH53276 (6 mg twice daily) coadministered with RTV. The study was designed to provide a proof of concept with a single dosing regimen of SCH53276 with RTV coadministration. Because inhibition of baseline HIV-1 viral load has been shown to correlate well with the trough levels of CCR5 inhibitors, a twice-daily dosing regimen with RTV coadministration was selected over a once-daily dosing regimen to produce higher trough level concentrations of SCH53276 at steady state. The safety of this dosing regimen was confirmed previously in the RMD study in healthy volunteers. Methods This study was a single-centre, open-label, nonrandomized trial of SCH53276 with concurrent RTV. Study drug (6 mg every h) was given for 1 days as an oral solution (3 ml per dose). RTV (1 mg capsule) was administered once daily. Following the 1-day dosing period, patients received no treatment for 14 days (the washout) and commenced combination antiretroviral therapy on day 25. The study was open to currently untreated HIV-1- infected patients with R5-tropic virus only. Participants were antiretroviral-naive or had had a 3-month treatment interruption. Other key inclusion criteria were age years, body mass index (BMI) kg/ m 2, CD4 + T-cell count 1 cells/µl and plasma HIV-1 RNA 5, copies/ml. Key exclusion criteria were resistance to 2 classes of antiretroviral agents, prior CCR5 antagonist use, an active AIDS-defining illness and detectable dual-tropic or X4-tropic virus. The primary endpoint was change in plasma HIV-1 RNA from baseline to day 1 of treatment. Clinical and laboratory evaluations Screening assessments included CD4 + T-cell count, plasma HIV-1 RNA, tropism, HIV-1 genotype (Trugene HIV-1 Guidelines TM Rules 1., Bayer Health Care, Tarrytown, NY, USA), haematological, renal (estimated glomerular filtration rate) and hepatic safety laboratories, a urinary drug screen and pregnancy test (as applicable). Plasma HIV-1 RNA, CD4 + T-cell count, safety laboratories and HIV-1 tropism were repeated on the day prior to receipt of study drug. Plasma HIV-1 RNA was determined with the Roche Amplicor assay (Roche Molecular Diagnostics, Pleasanton, CA, USA) on days 1, 3, 5, 7, 1, 15, 2 and 25. CD4 + T-cell count was quantified on days 1 and 25. Tropism assays were performed at four time points: at screening and at days -1, 1 and 25 using the Viro- Tect Tropism assay (Invirion Diagnostics, Oak Brook, IL, USA), a flow cytometric technique with a sensitivity cutoff of 1% for detection of CCR5- and CXCR4- infected cells. Laboratory tests were performed on days 5, 1 and 25. Vital signs were assessed on days 1 and 1 of dosing, and on day 25. Resting electrocardiograms (ECGs) were performed at days 1 and 25 only. The National Cancer Institute s Common Terminology Criteria for Adverse Events version 3. [7] was used for toxicity grading. Intensive PK sampling was performed on day 1, immediately pre-dosing, and at.5, 1, 1.5, 2, 4, 6 and h after dosing. This PK sampling schedule was repeated on day 1. All patients were confined for 14 h on days 1 and 1. Trough (pre-dose) PK samples were also obtained on days 3, 5 and 7. PK samples were analysed using a validated liquid chromatographic-tandem mass spectrometric method with a calibration range of.5 1, ng/ml. Statistical and pharmacokinetic data analyses Data from all enrolled patients were included in the tabular and graphical summaries of change in HIV-1 RNA from baseline over time. In addition, the proportion of patients with plasma HIV-1 RNA<5 copies/ ml and the proportion of patients with a decrease in plasma HIV-1 RNA of 1 log 1 copies/ml were calculated at day 1. The C max and T max were determined by observation of the plasma concentration time data. The AUC up to the last measured concentration following the first dose of SCH53276 and RTV were calculated using the linear trapezoidal method. Plasma samples were drawn for a h post-dose period on days 1 and 1. This allowed estimation of exposure over the dosing interval (τ) and also calculation of the accumulation ratio (steady state AUC/first dose AUC), while keeping patient blood sampling burden low. Characterization of terminal elimination phase was not possible 1 29 International Medical Press
3 SCH53276 in HIV type-1-infected patients Figure 1. HIV-1 RNA evolution during receipt of SCH53276 with ritonavir (days 1 1), no therapy (days 11 24) and commencement of combination antiretroviral therapy (day 25) Plasma HIV-1 RNA change from baseline, log 1 copies/ml Viral load <5 copies/ml ( ) -1.6 ( ) -.4 ( ) -2 Period of dosing Days n Data points are mean change in HIV type-1 (HIV-1) viral load (95% confidence interval). because of the relatively short blood sampling period. However, effective t ½ was calculated based on the accumulation ratio, as previously described [8]. The apparent steady state total body clearance was calculated as dose/auc τ. Results The study enrolled Caucasian male participants. Median age was 36 years (range 3 52) and median BMI was 24.3 kg/m 2 (range 2 28). Median CD4 + T-cell count and plasma HIV-1 RNA were 327 cells/µl (range 17 1,8) and 4.6 log 1 copies/ml (range ), respectively. Four patients were antiretroviral-naive and eight were treatment-experienced, but off therapy for a median of 32 months (range 3 71). Mean (95% confidence interval [CI]) changes from baseline plasma HIV-1 RNA at days 1 and 15 (4 days after study drug ceased) were log 1 copies/ml ( ) and log 1 copies/ml ( ), respectively (Figure 1). Overall, 1 of (83%) patients exhibited a decrease of 1 log 1 copies/ ml in plasma HIV-1 RNA at day 1 (Table 1). Two patients at day 15 and one at day 2 achieved plasma HIV-1 RNA<5 copies/ml. All virus isolates remained R5-tropic throughout the study period. There was an increase in CD4 + T-cell count between days -1 and 1 (mean increase of 59 cells/µl). CD4 + T-cell count had returned to baseline by day 25. The mean steady state C min, C max and AUC τ values in HIV-1-infected individuals (Table 2) were comparable with those observed in healthy seronegative volunteers. The mean effective t ½ was calculated at 39.4 h, which was considerably longer than the h dosing period. In total, 11 (92%) patients reported 1 treatmentemergent adverse events (AEs), most commonly gastrointestinal upset (67%), that is, diarrhoea (33%) and abdominal pain (25%). Gastrointestinal disorders reported in <1% were abdominal distension, nausea, abdominal pain (upper and lower) and frequent bowel movement. Overall, 75% of AEs were graded as mild; 58% were considered by clinicians at the site to be likely related to RTV [6] and unlikely related to SCH One serious AE was recorded in a 32-year-old male, who reported chest pain and mild dyspnoea on day 23 (13 days after last receiving study drug). Pericarditis (grade 2) was diagnosed based on ECG changes, although it was not confirmed by echocardiogram. In the absence of a confirmed aetiology, the event was considered possibly related to the study drug. All symptoms and ECG changes resolved without sequelae after 4 days; the patient did not require hospital admission and was treated with 4 days of overthe- counter simple analgaesia. None of the changes in haematological and biochemical parameters was considered clinically significant by clinicians at the site. The median change in QTc interval at day 1 from baseline was ms (range -36 6). Discussion Ten days of dosing with SCH53276 coadministered with RTV demonstrated potent antiretroviral activity in this small study. The maximum reductions in plasma HIV-1 RNA observed at day 15 (4 days after last receipt Antiviral Therapy
4 SL Pett et al. of study drug) are similar to those previously observed with two other small molecule CCR5 antagonists, maraviroc [2] and vicriviroc [4,5]. In addition, the mean C min level of SCH53276 (178 ng/ml) in this study was above the 1 ng/ml C min value shown to correlate with better virological suppression in both maraviroc [9] and vicriviroc [1] trials. CXCR4-using virus was not detected during this brief, 1-day treatment. SCH53276 was generally well tolerated with no signature adverse reactions. The patient diagnosed with pericarditis 13 days after last dosing of study drug recovered quickly and without sequelae. Relationship of this event to SCH53276 was considered possible, despite the length of time between last receipt of study drug and onset of symptoms. Small molecule CCR5 antagonists are becoming an important addition to the antiretroviral armamentarium. SCH53276 represents a promising future treatment option. The high virological efficacy of this drug is supported by the finding that the trough concentrations of SCH53276, when dosed with concurrent RTV, exceed the in vitro IC 9 (1.1 ng/ml) by >3-fold (after correction for 8% plasma protein binding). In addition, the long t ½ justifies once-daily dosing. Acknowledgements In addition to all the patients who participated in this study, we would like to acknowledge John McAllister, Mark Lacey, Martina Rafferty and Brett Sinclair of the HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia; Linda Hotong, Kate Towers and Jane Donnelly of the Clinical Trials Pharmacy Unit, St Vincent s Hospital; Fiona Peet and Erika O Dea of the Clinical Trials Centre, St Vincent s Hospital; and Jack Tseng of Schering Plough Research Institute (SPRI), Kenilworth, NJ, USA. The study was coordinated by the National Centre in HIV Epidemiology and Clinical Research, Sydney, Australia and conducted at St Vincent s Hospital. The National Centre in HIV Epidemiology and Clinical Research is funded by the Australian Government Department of Health and Ageing and is affiliated with the Faculty of Medicine, University of New South Wales, Darlinghurst, Sydney, Australia. The trial was conducted in accordance with the ICH Good Clinical Practice guidelines. Informed consent was obtained from all patients. The study was approved by the St Vincent s Hospital and the University of New South Wales Human Research Ethics Committees using the human experimentation guidelines in the National Statement on Ethical Conduct in Research Involving Humans issued by the National Health and Medical Research Council, Commonwealth of Australia. Disclosure statement This study was supported with funds from SPRI. MM, AT and JMS are employees of SPRI. The Biostatistical Unit of SPRI provided data analyses. Table 1. Distribution of HIV type-1 RNA log 1 copies/ml decrease by time interval Day of study n <, n (%) to <1, n (%) 1 to <2, n (%) 2, n (%) Receipt of study drug Day 3 1 a 5 (5) 5 (5) () () Day 5 1 (8) 1 (83) 1 (8) () Day 7 () 6 (5) 6 (5) () Day 1 () 2 (17) 9 (75) 1 (8) Washout (no drug) Day 15 () 1 (8) 7 (58) 4 (33) Day 2 1 (8) 6 (5) 3 (25) 2 (17) Day 25 1 (8) 9 (75) 2 (17) () a Missing data for two patients. Table 2. Pharmacokinetic parameters of SCH53276 on days 1 and 1 Day of study C max, ng/ml C min, ng/ml Median T max, h (range) AUC h, ng h/ml Cl ss /F, l/h Effective t ½, h Day (37) 35.6 (26) 1.5 (1. 6.) 586 (27) NA NA Day (15) 178 (19) 1.4 (1. 4.) 2,78 (16) 17.7 (15) 39.4 (37) Data are means (coefficient of variation %) unless otherwise indicated. AUC h, area under the plasma concentration time curve from baseline to h; Cl ss /F, apparent steady state total body clearance; C max, maximum plasma drug concentration; C min, minimum plasma drug concentration at pre-dose; NA, not applicable; T max, time to maximum concentration, t 1/2, half-life International Medical Press
5 SCH53276 in HIV type-1-infected patients References 1. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997; 185: Fätkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 25; 11: Selzentry (maraviroc). Prescribing information. (Updated 7 August 27. Accessed 1 September 28.) Available from 4. Schürmann D, Fätkenheuer G, Reynes J, et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIVinfected adults. AIDS 27; 21: Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV- 1-Infected, treatment-experienced patients: AIDS Clinical Trials Group J Infect Dis 27; 196: Norvir (ritonavir). Product monograph July 27. Abbott Laboratories, North Chicago, IL, USA. 7. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.. (Updated 4 March 28. Accessed 1 September 28.) Available from applications/docs/ctcaev3.pdf 8. Boxenbaum H, Battle M. Effective half-life in clinical pharmacology. J Clin Pharmacol 1995; 35: McFayden L, Jacqmin P, Wade JR, Weatherley B. Maraviroc exposure-efficacy (<5 copies/ml) analysis in HIV-1-infected treatment-naive subjects - ITT Population (MERIT Study). XVII International AIDS Conference. 3 8 August 28, Mexico City, Mexico. Poster TUPE Zingman B, Suleiman J, DeJesus E, et al. Vicriviroc in combination with an optimised antiretroviral regimen for treatment-experienced subjects, the VICTOR-E1 trial. 15th Conference on Retroviruses and Opportunistic Infections. 3 6 February 28, Boston, MA, USA. Poster Accepted for publication 23 September 28 Antiviral Therapy
Clinical Study Report AI Final 28 Feb Volume: Page:
Study Design, Continued Electrocardiogram (ECG) and vital sign assessments were done at select times during the study. Blood and urine samples for clinical laboratory evaluations were collected at specified
More informationSingle and Multiple Dose Pharmacokinetics and Safety in Non-HIV-Infected Healthy Subjects Dosed with BMS , an Oral HIV Attachment Inhibitor
Single and Multiple Dose Pharmacokinetics and Safety in on-hiv-infected Healthy Subjects Dosed with 66368, an Oral HIV Attachment Inhibitor Richard ettles, Caly Chien, Erica Elefant, Xiaodong Wang, Ellen
More informationPoster O_16. Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA; 2. Lifetree Clinical Research, Salt Lake City, UT, USA
Poster O_16 Lack of PK Interaction Between the HCV Protease Inhibitor MK-5172 and Methadone and Buprenorphine/Naloxone in Subjects on Stable Opiate Maintenance Therapy Iain Fraser, 1 Wendy W. Yeh, 1 Christina
More informationMedian (Min Max) CVC 100 mg + EFV placebo + TDF/FTC (N=8) CVC 200 mg + EFV placebo + TDF/FTC (N=10) LLOQ=5.00 ng/ml Time (h)
600 Pharmacokinetics (Pk) of cenicriviroc (cvc) following 100 or 200 mg once-daily Dosing with open-label tenofovir / emtricitabine (tdf/ftc) in hiv-1 infected subjects enrolled in a Phase 2b study David
More informationJennifer R King, Amit Khatri, Roger Trinh, Bifeng Ding, Jiuhong Zha and Rajeev Menon AbbVie Inc.
Pharmacokinetics of Darunavir, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir and Ribavirin in Adults Infected with Hepatitis C Virus (HCV) Genotype 1 and Human Immunodeficiency Virus (HIV) Jennifer R
More informationThe US Food and Drug Administration has
NEW ANTIRETROVIRAL AGENTS FOR TREATMENT-EXPERIENCED PATIENTS * Roy M. Gulick, MD, MPH ABSTRACT Antiretroviral treatment regimens currently available for the treatment of the human immunodeficiency virus
More informationPRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients
PRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients Jay Lalezari, Kush Dhody, Ula Kowalczyk, Kazem Kazempour, Nader Pourhassan, and Paul J. Maddon 1 ASM Microbe 2016
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationJohnson & Johnson Pharmaceutical Research & Development, L.L.C.
SYNOPSIS Issue Date: 27 April 2009 Document No.: EDMS-PSDB-9908562:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient Johnson & Johnson Pharmaceutical Research & Development,
More informationPK-PD modelling to support go/no go decisions for a novel gp120 inhibitor
PK-PD modelling to support go/no go decisions for a novel gp120 inhibitor Phylinda LS Chan Pharmacometrics, Pfizer, UK EMA-EFPIA Modelling and Simulation Workshop BOS1 Pharmacometrics Global Clinical Pharmacology
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationReceived 25 May 2010/Returned for modification 20 February 2011/Accepted 30 March 2011
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2011, p. 2768 2774 Vol. 55, No. 6 0066-4804/11/$12.00 doi:10.1128/aac.00713-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Pharmacokinetics
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationPediatric Patient Information:
New pediatric dosing information for Aptivus, patients 2-18 years of age, approval of New Oral Solution and information on coadministration with midazolam Aptivus (tipranavir) is now available as an oral
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationResults. Subject Disposition and Demographics Of 37 enrolled subjects, 23 (62.2%) completed the study
Poster 5-20 Effect of Gastric ph on the Bioavailability of in Healthy Subjects James Longstreth, PhD, Marijke H. Adams, PharmD, PhD, 2 Vasi Sperry, PhD, 3 Dan Kajdasz, PhD, 3 Carol R. Reed, MD 3 Longstreth
More informationComparison of GW (908) Single Dose and Steady-state Pharmacokinetics (PK): Induction Potential and AAG Changes (APV10013)
43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Poster A-1607 Comparison of GW433908 (908) Single Dose and Steady-state Pharmacokinetics (PK): Induction Potential and AAG
More informationMerck Sharp & Dohme Corp., The Netherlands; Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA; Yale University, New Haven, CT, USA;
Pharmacokinetic Interaction Between HCV Protease Inhibitor Boceprevir and Methadone or Buprenorphine/Naloxone in Subjects on Stable Maintenance Therapy Ellen GJ Hulskotte, 1 Hwa-Ping Feng, 2 R Douglas
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More information17 th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy June 10, 2016 Washington, DC
MK-3682, a HCV NS5B Inhibitor with a Broad Spectrum of HCV Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotypes -1,-2, and -3 HCV-Infected Patients Nancy Kim 1 *, Wei Gao 1, Xiaoli Shirley
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationEffect of Multiple-Dose Ketoconazole and the Effect of Multiple-Dose Rifampin on Pharmacokinetics (PK) of the HCV NS3 Protease Inhibitor Asunaprevir
Effect of Multiple-Dose Ketoconazole and the Effect of Multiple-Dose Rifampin on Pharmacokinetics (PK) of the HCV NS3 Protease Inhibitor Asunaprevir Eley T, 1 He B, 1 Huang S-P, 2 Stonier M, 1 Bedford
More informationGlobal Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 2003, p. 350 359 Vol. 47, No. 1 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.1.350 359.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More information2.0 Synopsis. ABT-333 M Clinical Study Report R&D/09/956
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-333 Volume: Name of Active Ingredient: Page: Sodium N-{6-[3-tert-butyl-5-(2,4-
More informationNational AIDS Treatment Advocacy Project
National AIDS Treatment Advocacy Project Nelfinavir: general information, study results (CD4 and viral load), dosing schedule, eating instructions, drug interactions, combination with other protease inhibitors
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationART Treatment. ART Treatment
Naïve Experienced Strategies ARV in pregnancy ART Treatment Naïve studies: ART Treatment Abstract 37 Atazanavir/r vs Lopinavir/r: Castle study Abstract 774 Kivexa vs Truvada: HEAT study Abstract 775 Lopinavir/r
More informationEffect of Daclatasvir/Asunaprevir/Beclabuvir in Fixed-dose Combination on the Pharmacokinetics of CYP450/Transporter Substrates In Healthy Subjects
Effect of Daclatasvir/Asunaprevir/Beclabuvir in Fixed-dose Combination on the Pharmacokinetics of CYP450/Transporter Substrates In Healthy Subjects Xiaolu Tao 1, Karen Sims 1, Yi-Ting Chang 1, Jignasa
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationDrug-Drug Interaction Study of Ketoconazole and Ritonavir-boosted Saquinavir ACCEPTED
AAC Accepts, published online ahead of print on 17 November 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.00769-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationSafety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects
nature publishing group ARTICLES Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects M Iwamoto 1, LA Wenning 1, AS Petry 1, M Laethem 1, M De Smet
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationThe results of the ARTEN study. Vicente Soriano Hospital Carlos III, Madrid, Spain
The results of the ARTEN study Vicente Soriano Hospital Carlos III, Madrid, Spain Nevirapine: a well-defined efficacy and tolerability profile High efficacy levels 1 3 Well-defined safety profile 4 Favourable
More informationDidactic Series. CROI New Antiretroviral Therapies. Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016
Didactic Series CROI 2016 - New Antiretroviral Therapies Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016 This project is supported by the Health Resources and
More informationPharmacokinetic Interaction Between Norgestimate/Ethinyl Estradiol and EVG/COBI/FTC/TDF Single Tablet Regimen
Pharmacokinetic Interaction Between Norgestimate/Ethinyl Estradiol and EVG/COBI/FTC/TDF Single Tablet Regimen Polina German, Maggie Wang, David Warren and Brian Kearney Gilead Sciences Foster City, CA,
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationPharmacodynamics, Safety, and Pharmacokinetics of BMS , an Oral HIV-1 Attachment Inhibitor in HIV-1 Infected Subjects
MAJOR ARTICLE Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1 Infected Subjects Richard E. Nettles, 1,a,b Dirk Schürmann, 4,a Li Zhu, 1 Michele
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationBackground: Narlaprevir (SCH )
Once Daily Narlaprevir (SCH 9518) in Combination with Peginterferon alfa-2b/ Ribavirin for Treatment-Naive Patients with Genotype-1 Chronic Hepatitis C: Interim Results from the NEXT-1 Study Vierling J,
More informationIndividual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424136
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationGeneric lopinavir/ritonavir is bioequivalent to Aluvia but neither result in adequate lopinavir exposure at 50% dose reduction: HIV-NAT 085
Generic lopinavir/ritonavir is bioequivalent to Aluvia but neither result in adequate lopinavir exposure at 50% dose reduction: HIV-NAT 085 Reshmie Ramautarsing, Meena Gorowara, Jasper van der Lugt, Jiratchaya
More informationClinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents 1 Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in
More informationshort-term safety and tolerability of coadministration of ETR or DRV/rtv and artemether/lumefantrine in healthy subjects.
SYNOPSIS Issue Date: 6 March 2012 Name of Sponsor/Company Janssen EMEA Medical Affairs Name of Finished Product INTELENCE ; PREZISTA Name of Active Ingredient(s) etravirine (ETR, also known as TMC125);
More information2018 F. Hoffmann-La Roche Ltd. All rights reserved.
PRELIMINARY EVIDENCE FOR PHARMACODYNAMIC EFFECTS OF RG7916 IN JEWELFISH A STUDY IN PATIENTS WITH SPINAL MUSCULAR ATROPHY WHO PREVIOUSLY PARTICIPATED IN A STUDY WITH ANOTHER SMN2-SPLICING TARGETING THERAPY
More informationPharmacokinetics and Drug Interaction Profile of Cobicistat boosted-elvitegravir with Atazanavir, Rosuvastatin or Rifabutin
Pharmacokinetics and Drug Interaction Profile of Cobicistat boosted-elvitegravir with Atazanavir, Rosuvastatin or Rifabutin S Ramanathan, H Wang, T Stondell, A Cheng, and BP Kearney Gilead Sciences, Inc.,
More informationA Double-Blind, Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R5 HIV-1
MAJOR ARTICLE A Double-Blind, Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R5 HIV-1 Michael Saag, 1 James Goodrich, 2 Gerd Fätkenheuer, 3 Bonaventura Clotet,
More informationAbout the MODERN study About maraviroc
ViiV Healthcare presents phase III data comparing once-daily maraviroc in combination with darunavir/ritonavir with emtricitabine/tenofovir plus darunavir/ritonavir in treatment-naïve adults with HIV-1
More informationPhysiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters
Physiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters Qi Wang, Wenying Li, Ming Zheng, Timothy Eley, Frank
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBASIC AND TRANSLATIONAL SCIENCE
BASIC AND TRANSLATIONAL SCIENCE Prediction of Virological Response and Assessment of Resistance Emergence to the HIV-1 Attachment Inhibitor BMS-626529 During 8-Day Monotherapy With Its Prodrug BMS-663068
More informationCombination therapy with simeprevir and TMC647055/low dose ritonavir: dose anticipation using PBPK modeling and dose optimization in healthy subjects
Combination therapy with simeprevir and TMC647055/low dose ritonavir: dose anticipation using PBPK modeling and dose optimization in healthy subjects MC. Rouan, J. Snoeys, S. Ouwerkerk-Mahadevan, R. Verloes,
More informationLê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group
Lê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group 1 AP-HP, Hopital Bichat, Pharmacology-Toxicology, Paris, France, 2 IAME, UMR 1137,
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationLack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids
Blackwell Science, Ltdxford, UKBJCPBritish Journal of Clinical Pharmacology0306-5251Blackwell Science, 200254riginal Articleseltamivir and antacids lack of kinetic interactionp. Snell et al. Lack of pharmacokinetic
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 December 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 December 2011 PREZISTA 400 mg, film-coated tablet B/60 (CIP code: 393 138-3) Applicant: JANSSEN-CILAG darunavir
More informationThe BATAR Study Boosted Atazanavir Truvada vs. Atazanavir Raltegravir
The BATAR Study Boosted Atazanavir Truvada vs. Atazanavir Raltegravir A Pilot Study of the Novel Antiretroviral Combination of Atazanavir and Raltegravir in HIV-1 Infected Subjects with Virologic Suppression
More informationICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
More informationMaraviroc Pharmacokinetics in Blood Plasma, Genital Tract Fluid and Tissue in Healthy Female Volunteers
Maraviroc Pharmacokinetics in Blood Plasma, Genital Tract Fluid and Tissue in Healthy Female Volunteers Julie B. Dumond, Kristine B. Patterson, Allison Pecha, Rebecca E. Werner, Emma Andrews,* Bharat Damle,*
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More informationSupplementary Table 1: Summary of 33 Patients Treated with Abemaciclib in Dose Escalation
Supplementary Table 1: Summary of 33 Patients Treated with Abemaciclib in Dose Escalation Cohort Dose and Frequency Age and Sex Tumor Type Number of Cycles Best Overall Response 4M Colorectal cancer -
More informationPharmacological determinants of long-term treatment success
Professor David Back Liverpool, UK Pharmacological determinants of long-term treatment success Pharmacological Issues with Antiretroviral Therapy Intrinsic potency Bioavailability Effect of food and other
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationEvaluation of Drug-Drug Interactions Between Sofosbuvir/Velpatasvir/Voxilaprevir and Boosted or Unboosted HIV Antiretroviral Regimens
Evaluation of Drug-Drug Interactions Between Sofosbuvir/Velpatasvir/Voxilaprevir and Boosted or Unboosted HIV Antiretroviral Regimens Kimberly L. Garrison, Erik Mogalian, Heather Zhang, Grace Ma, Steve
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationTreatment of HIV-1 in Adults and Adolescents: Part 2
Treatment of HIV-1 in Adults and Adolescents: Part 2 Heather E. Vezina, Pharm.D. University of Minnesota Laboratory Medicine & Pathology Experimental & Clinical Pharmacology wynnx004@umn.edu Management
More informationBRINCIDOFOVIR WAS USED TO SUCCESSFULLY TREAT ADENOVIRUS INFECTIONS IN SOLID ORGAN TRANSPLANT RECIPIENTS AND OTHER IMMUNOCOMPROMISED PATIENTS
BRINCIDOFOVIR WAS USED TO SUCCESSFULLY TREAT ADENOVIRUS INFECTIONS IN SOLID ORGAN TRANSPLANT RECIPIENTS AND OTHER IMMUNOCOMPROMISED PATIENTS Diana F. Florescu, MD 1, Michael S. Grimley, MD 2, Genovefa
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationStudy No: LOV OMA-104 Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationDrug Interactions Between Direct-Acting anti-hcv Antivirals Sofosbuvir and Ledipasvir and HIV Antiretrovirals
Drug Interactions Between Direct-Acting anti-hcv Antivirals Sofosbuvir and Ledipasvir and HIV Antiretrovirals Polina German, Philip S Pang, Steve West, Lingling Han, Karim Sajwani and Anita Mathias Gilead
More informationSYNOPSIS OF RESEARCH REPORT (PROTOCOL BC20779)
TITLE OF THE STUDY / REPORT No. / DATE OF REPORT INVESTIGATORS / CENTERS AND COUNTRIES Clinical Study Report Protocol BC20779: Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase
More informationBHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh
BHIVA Best of CROI Feedback Meetings London Birmingham North West England Cardiff Gateshead Edinburgh BHIVA Best of CROI Feedback Meetings 2010 ANTIRETROVIRAL TREATMENT STRATEGIES AND NEW DRUGS A5202:
More informationUpdate on HIV-1 Drug Resistance and Tropism Testing
Update on HIV-1 Drug Resistance and Tropism Testing Daniel R. Kuritzkes, MD Section of Retroviral Therapeutics Brigham and Women s Hospital Harvard Medical School ACTHIV 2011: A State-of-the-Science Conference
More informationIndividual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424138
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Atazanavir () Individual Study Table Referring to the Dossier (For National Authority Use Only)
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN
PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN Summary of Risk Management Plan for PREZISTA (Darunavir [TMC114]) This is a summary of the risk management plan (RMP) for PREZISTA. The RMP details important
More informationRenal Impairment From Dettli to Guideline: What can we learn?
Renal Impairment From Dettli to Guideline: What can we learn? SocraMetrics GmbH Mainzerhofplatz 14 99084 Erfurt phone: ++49-361-6020526 fax: ++49-361-6020525 e-mail: meinolf.wonnemann@socrametrics.de SocraMetrics
More information12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter
EACS 2009 11-14, November 2009 Cologne, Germany Course Director Jürgen K. Rockstroh, MD Co-Chairman, 12th European AIDS Conference Professor, University of Bonn Bonn, Germany Faculty Calvin Cohen, MD,
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME /GENERIC DRUG NAME: Vfend /Voriconazole
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN
PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN Summary of Risk Management Plan for REZOLSTA This is a summary of the risk management plan (RMP) for REZOLSTA. The RMP details important risks of REZOLSTA,
More informationDevelopment of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir
Development of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide () Bryan Baugh 1, Erika Van Landuyt 2, Simon Vanveggel 2, Herta
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More information